The demand for extracorporeal blood treatment is expected to upsurge owing to the growth of kidney diseases.
New York, NY -- (SBWIRE) -- 05/11/2017 -- Blood purification has always been viewed as a branch of medicine which is extremely crucial and complicated. In 1950's after the breakthrough of clinical dialysis different manufacturers invested in latest technologies and started as a supplier of extracorporeal blood treatment. The extracorporeal blood treatment is a type of filtration method used to remove many toxins from the blood. By the end of 1960's, a company named B Braun started to manufacture its own dialysis machine. As the number of manufacturers increased, the use of these dialysis machines brought upon patient safety issues. In the 1980's extracorporeal blood treatment systems became significantly user-friendly as there was more and more digitalization in these systems.
Extracorporeal Blood Treatment Market: Drivers and Restraints
The demand for extracorporeal blood treatment is expected to upsurge owing to the growth of kidney diseases. The demand for kidney dialysis has increased as the prevalence of chronic conditions such as hypertension, heart diseases and diabetes are on a rise along with the elderly population. International statistics has shown that as compared to other advanced countries such as Japan, U.S. has a higher rate of dialysis utilization. In 1960, the first dialysis center was started and the establishment of Medicare's End Stage Renal Disease Program ensured the coverage of expensive dialysis treatment. From its establishment in 1973, around 400,000 people have received dialysis under the Medicare's End Stage Renal Disease Program.
Extracorporeal blood treatment is a purification process that takes place outside the body. The blood passes through the membrane, filters the waste or molecules within the extracorporeal region and returning to normal state. Purified blood is then returned back to the patient's body suffering from kidney injury.
The growth of the dialysis facilities in the U.S. has increased by 6% annually over the past five years. There has been an increase in the population of U.S. diagnosed with end-stage renal disease.
According to the data provided by the U.S. Renal Data System, in 2013 the number of patient who underwent dialysis were 468,000. The 47 fold increase in the dialysis procedure in the past 40 years is driven by the rise in diabetes and other chronic conditions.
Extracorporeal Blood Treatment Market: Region-wise Outlook
In terms of geography, extracorporeal blood treatment market has been divided into five regions including North- America, Asia- Pacific, Middle-East & Africa, Latin America and Europe. North America region dominated the extracorporeal blood treatment market owing to the presence of undisputed market players, the presence of strong research developments and presence of insurance coverage. For instance, Baxter presented their study on the role of extracorporeal blood purification in the removal of molecules which leads to inflammation. Economically developing region such as Asia Pacific is expected to be the fastest growing with the presence of huge population base and also an increase in the number of patient undergoing dialysis.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/15685
Extracorporeal Blood Treatment Market: Key Market Participants
Some of the extracorporeal blood treatment market participants are Fresenius Medical Care N.A., DaVita Kidney Care, U.S. Renal Care, Dialysis Clinic Inc., American Renal Associates, Satellite Healthcare, Atlantic Dialysis Management, Northwest Kidney Centers, Centers for Dialyssis Care and Rogosin Institute.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/15685